2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159920
    PSB-22269 98%
    PSB-22269 is a GPR17 antagonist with a Ki value of 8.91 nM. PSB-22269 further demonstrated significant inhibitory effects in cAMP and G protein activation assays. Molecular docking studies revealed that the binding site of PSB-22269 contains positively charged arginine residues and a hydrophobic pocket. PSB-22269 provides a strategy to promote remyelination and holds promise for research in the field of multiple sclerosis.
    PSB-22269
  • HY-159925
    QKY-613 2646682-38-2 98.24%
    QKY-613 is a prodrug that enhances immune surveillance by targeting nucleic acid modification pathways. QKY-613 promotes the selective incorporation of 6mdA (N6-methyldeoxyadenosine) into viral DNA, enhancing the phase separation potential of DNA, thereby increasing the activation of cGAS and strengthening host immune surveillance. In virus-infected mouse models, QKY-613 significantly reduced mortality in aged mice. QKY-613 holds promise for research on nucleic acid modification-based immune surveillance mechanisms.
    QKY-613
  • HY-159926
    Tixanox sodium 40691-57-4 98%
    Tixanox sodium (RS-7540), an anti-allergic compound, is a potent inhibitor of mediator release in the IgE-mediated passive cutaneous anaphylaxis (PCA) reaction.
    Tixanox sodium
  • HY-159927
    TAK-661 175215-34-6 98%
    TAK-661 is a inhibitor of eosinophil chemotaxis. TAK-661 significantly reduces the bronchoconstriction during the late phase, along with the inhibition of eosinophilia in bronchoalveolar lavage (BAL) and the eosinophil infiltration into the airway wall.
    TAK-661
  • HY-159952
    ALK5-IN-84 98%
    ALK5-IN-84 (Compound 23) is an ALK5 inhibitor with a pKi value of 9.35 against hALK5. When administered via inhalation, ALK5-IN-84 exhibits significant ALK5 inhibitory activity. ALK5-IN-84 is promising for the development of inhaled ALK5 inhibitors.
    ALK5-IN-84
  • HY-159965
    NOD1-RIPK2-IN-1 98%
    NOD1-RIPK2-IN-1 (Compound 37) is a NOD1-RIPK2 signaling pathway inhibitor with IC50 values of 42 nM and 1.52 nM for NOD1 and RIPK2, respectively. NOD1-RIPK2-IN-1 reduces the secretion of the pro-inflammatory cytokine IL-8 and can be used in the research of inflammation and immune-related diseases.
    NOD1-RIPK2-IN-1
  • HY-160000
    Coumaperine 76733-91-0
    Coumaperine is an amide alkaloid. Coumaperine can be extracted from white piper. Coumaperine inhibits NF-κB. Coumaperine derivatives exhibit anticancer activity against non-small cell lung cancer and Hodgkin's lymphoma. Coumaperine derivatives have antibacterial activity.
    Coumaperine
  • HY-160021
    RORγt agonist 4 2241769-59-3 98%
    RORγt agonist 4 (compound 14) is a potent and selective agonist of RORγt. RORγt agonist 4 significantly enhances metabolic stability. RORγt agonist 4 improves the situation of tumor models of mouse B16F10 melanoma and LLC lung adenocarcinoma.
    RORγt agonist 4
  • HY-160026
    IL-17 modulator 8 1608097-49-9 98%
    IL-17 modulator 8 (compound 286) is an orally active modulator of IL-17. IL-17 modulator 8 significantly reduces IL-6, IFN-γ, and edema. IL-17 modulator 8 can used in study arthritis.
    IL-17 modulator 8
  • HY-160027
    TNF-alpha-IN-1 98%
    TNF-alpha-IN-1 (compound 202) is an orally active inhibitor of TNF-alpha. TNF-alpha-IN-1 has anti-inflammatory activity which can used in study rheumatoid arthritis, psoriasis, and asthma.
    TNF-alpha-IN-1
  • HY-160028
    IL-17 modulator 9 1449211-26-0 98%
    IL-17 modulator 9 (compound 453) is an orally active modulator of IL-17. IL-17 modulator 9 significantly reduces IL-6, IFN-γ, and edema. IL-17 modulator 9 can used in study inflammation.
    IL-17 modulator 9
  • HY-160167
    Birelentinib 2662512-15-2 98%
    Birelentinib (DZD8586) is an orally effective, selective, non-covalent inhibitor targeting LYN tyrosine kinase and BTK tyrosine kinase, capable of penetrating the blood-brain barrier. Birelentinib exhibits concentration-dependent antiproliferative effects in RI-1 cells and diffuse large B-cell lymphoma (DLBCL) cell lines carrying BTK resistance mutations (such as C481X, V416L, etc.). Birelentinib blocks both BTK-dependent and independent signaling of the B-cell receptor (BCR), thereby inhibiting tumor cell proliferation and inducing cell death. Birelentinib can be used in research to overcome resistance to existing covalent and non-covalent BTK inhibitors in B-cell non-Hodgkin lymphoma (B-NHL).
    Birelentinib
  • HY-160168
    BTK-IN-31 98%
    BTK-IN-31 (Compound 2) is a selective, non-covalently reversible, and blood-brain barrier (BBB) permeable Btk inhibitor. BTK-IN-31 has research potential in immune disorders, cancer, cardiovascular disease, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders.
    BTK-IN-31
  • HY-160180
    Glucocorticoid receptor agonist-4 Ala-Ala-Mal 3014393-37-1 98%
    Glucocorticoid receptor agonist-4 Ala-Ala-Mal (Compound Preparation 9) is an anti-human TNFα antibody-glucocorticoid receptor agonist (GC) conjugate. Glucocorticoid receptor agonist-4 Ala-Ala-Mal can be used in the study of autoimmune and inflammatory diseases.
    Glucocorticoid receptor agonist-4 Ala-Ala-Mal
  • HY-160184
    COX-1-IN-5 524699-85-2
    COX-1-IN-5 (example 13, compound PS13) is a potent and selective COX-1 inhibitor (COX-1 IC50 = 1 nM, COX-2 IC50 > 0.1 μM) exhibiting >1000-fold selectivity over COX-2. COX-1-IN-5 possesses strong anti-inflammatory, antipyretic, analgesic, antithrombotic, anti-cancer activities. COX-1-IN-5 can be used for COX-mediated diseases research, such as inflammatory conditions and pain. COX-1-IN-5 radiolabeled with 11C can be used as a selective PET tracer for whole‑body imaging of COX‑1 distribution and target engagement in vivo.
    COX-1-IN-5
  • HY-160216
    RIPK1-IN-18 2682889-01-4 98%
    RIPK1-IN-18 (compound i) is a potent inhibitor of RIPK1. RIPK1-IN-18 can be used in autoimmune diseases research.
    RIPK1-IN-18
  • HY-160223
    ssVACV-70mer sodium
    ssVACV-70mer sodium is a 70 bp single-stranded oligonucleotide containing viral DNA motifs that derive from the vaccinia virus DNA. Unlike its double-stranded counterpart dsVACV 70mer, ssVACV 70mer is not IFN-inducer.
    ssVACV-70mer sodium
  • HY-160227
    ORN 06 1116698-32-8
    ORN 06 (Compound R-0006), a U-rich single-stranded RNA (containing 6 repeats of the UUG sequence motif), is a TLR7/8 agonist. ORN 06 stimulates human TLR7/8-mediated or murine TLR7-mediated immunity.
    ORN 06
  • HY-160228
    ORN 02 937769-72-7
    ORN 02 is a synthetic single-stranded U-rich RNA and contains 6 repeats of UUAU sequence motif. The AU-rich oligoribonucleotides (ORNs) are able to stimulate TLR8.
    ORN 02
  • HY-160433
    TNF-α-IN-12 364039-56-5 98%
    TNF-α-IN-12 is a TNF-α inhibitor with IC50 of 0.1 μM. TNF-α-IN-12 can decrease the TNF-α blood levels.
    TNF-α-IN-12
Cat. No. Product Name / Synonyms Application Reactivity